Tapinarof Clinical Trials (2026): 19 Studies for Plaque Psoriasis & Atopic Dermatitis

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

19 Tapinarof clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 7 indications (including Plaque Psoriasis & Atopic Dermatitis) and 4,927 total planned enrollment. 9 Phase 3 Tapinarof trials and 3 Phase 2, 4 Phase 4 are listed. 3 Tapinarof clinical trials are actively recruiting. Most recent activity: NCT07352566 (Jun 2030).

Tapinarof clinical trials at a glance: phase × recruitment status

Phaseactive not recruitingenrolling by invitationcompletednot yet recruitingTotal
Early P111
P111
P2123
P2/P311
P3279
P4314

Recruiting Tapinarof clinical trials (3)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT07352566Utilization of a Microdevice for Psoriasis and Atopic DermatitisP4Psoriasis10Aug 2026
NCT05981118Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)P2/P3ICD10 Code L40.9 for Psoriasis40Jul 2024
NCT06661213Tapinarof for Cutaneous Lupus ErythematosusEarly P1Cutaneous Lupus Erythematosus10Apr 2025

Tapinarof clinical trials by indication

Plaque Psoriasis (6)

NCTAcronymPhaseStatusTitle
NCT05172726P3active not recruitingTapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
NCT07546214P1completedA Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.
NCT04053387P3completedLong Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
NCT03983980P3completedTapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
NCT03956355P3completedTapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
NCT04042103P2completedMaximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

Atopic Dermatitis (5)

NCTAcronymPhaseStatusTitle
NCT07265479AdoringP3active not recruitingA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
NCT05142774P3completedLong Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
NCT05014568P3completedTapinarof for the Treatment of Atopic Dermatitis in Children and Adults
NCT05032859DMVT-505-3102P3completedTapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
NCT05186805P2completedMaximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

Psoriasis (4)

NCTAcronymPhaseStatusTitle
NCT07352566P4not yet recruitingUtilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT06103695P4completedVtama in Psoriasis Patients Being Treated With Biologics.
NCT05789576P4completedA Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region
NCT05680740P4completedA Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis

Cutaneous Lupus Erythematosus (1)

NCTAcronymPhaseStatusTitle
NCT06661213Early P1enrolling by invitationTapinarof for Cutaneous Lupus Erythematosus

Plaque Type Psorisis (1)

NCTAcronymPhaseStatusTitle
NCT06742957P3completedStudy Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

Palmoplantar Keratoderma (1)

NCTAcronymPhaseStatusTitle
NCT06561321P2active not recruitingStudy to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma

ICD10 Code L40.9 for Psoriasis (1)

NCTAcronymPhaseStatusTitle
NCT05981118P2/P3enrolling by invitationComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)

Tapinarof pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
AdoringNCT07265479P3active not recruitingAtopic Dermatitis187
DMVT-505-3102NCT05032859P3completedAtopic Dermatitis406PMID 38777187

All Tapinarof trials (19)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT07352566Utilization of a Microdevice for Psoriasis and Atopic DermatitisP4not yet recruiting10University of California, San FranciscoAug 2026
NCT06561321Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar KeratodermaP2active not recruiting6Indiana UniversityOct 2024
NCT05981118Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)P2/P3enrolling by invitation40Wake Forest University Health SciencesJul 2024
NCT06661213Tapinarof for Cutaneous Lupus ErythematosusEarly P1enrolling by invitation10Northwestern UniversityApr 2025
NCT07265479AdoringA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisP3active not recruiting187Organon and CoDec 2025
NCT05172726Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsP3active not recruiting58Organon and CoDec 2021
NCT07546214A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.P1completed575Sun Pharmaceutical Industries, Inc.Oct 2025
NCT06742957Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque PsoriasisP3completed560Teva Pharmaceuticals USADec 2024
NCT05142774Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic DermatitisP3completed728Organon and CoOct 2021
NCT06103695Vtama in Psoriasis Patients Being Treated With Biologics.P4completed30Psoriasis Treatment Center of Central New JerseyFeb 2023
NCT05789576A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck RegionP4completed31Organon and CoMar 2023
NCT05680740A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque PsoriasisP4completed34Organon and CoDec 2022
NCT05014568Tapinarof for the Treatment of Atopic Dermatitis in Children and AdultsP3completed407Organon and CoSep 2021
NCT05032859DMVT-505-3102Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)P3completed406Organon and CoSep 2021
NCT05186805Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic DermatitisP2completed36Organon and CoNov 2021
NCT04053387Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)P3completed763Organon and CoAug 2019
NCT03983980Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)P3completed515Organon and CoJun 2019
NCT03956355Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)P3completed510Organon and CoMay 2019
NCT04042103Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque PsoriasisP2completed21Organon and CoJul 2019

Tapinarof clinical trials: frequently asked questions

How many Tapinarof clinical trials are there?
19 Tapinarof clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 13 are marked completed.
Are Tapinarof clinical trials recruiting in 2026?
Yes — 2 Tapinarof trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
What conditions is Tapinarof being studied for?
Tapinarof is being studied for Plaque Psoriasis, Atopic Dermatitis, Psoriasis, Plaque Type Psorisis, Palmoplantar Keratoderma and 2 more. The trials are grouped by indication on this page.
What phase is Tapinarof in?
Tapinarof clinical trials span 4 Phase 4, 9 Phase 3, 3 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Tapinarof clinical trials?
The lead sponsor across the most Tapinarof trials is Organon and Co, with 7 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Tapinarofas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: